You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Asuragen will use its Amplidex PCR tech to develop companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.
Two lawsuits represent two sides of genetic testing, the Economist writes: to know or not your risk of developing disease.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.
NPR reports on a clinical trial examining an antisense oligonucleotide drug for Huntington's disease.
The test will run on Oxford Nanopore's MinIon and will be used as a reflex test when the standard PCR test does not give a clear answer.
The researchers studied edits generated by more than 40,000 gRNAs and gathered data for more than 109 mutational outcomes to create the software.
A UK woman sues a hospital for not telling her of her father's genetic testing results, the Guardian reports.
In Science this week: molecular drivers of small cell neuroendocrine carcinomas, and more.
In PLOS this week: Huntington's disease modifiers, possible new Chikungunya virus subgroup, and more.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.